Free Trial
NASDAQ:MEDS

TRxADE HEALTH (MEDS) Stock Price, News & Analysis

TRxADE HEALTH logo
$2.80 +0.07 (+2.42%)
As of 02/21/2025

About TRxADE HEALTH Stock (NASDAQ:MEDS)

Key Stats

Today's Range
$2.66
$2.80
50-Day Range
$2.85
$8.13
52-Week Range
$3.69
$44.56
Volume
1,365 shs
Average Volume
207,831 shs
Market Capitalization
$3.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement; and designs, develops, owns, and operates a business-to-business web-based marketplace. It also distributes prescription medication, medical devices, and over the counter medication to pharmacies and medical clinics; and offers pricing transparency, purchasing capabilities, and other value-added services, as well as telehealth services. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. was founded in 2010 and is headquartered in Lutz, Florida.

Receive MEDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRxADE HEALTH and its competitors with MarketBeat's FREE daily newsletter.

MEDS Stock News Headlines

TRxADE HEALTH (NASDAQ:MEDS) Stock Price Down 5.9% - Here's Why
Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”
Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?
TRxADE Health (NASDAQ: MEDS)
Scienture Holdings, Inc. (SCNX)
See More Headlines

MEDS Stock Analysis - Frequently Asked Questions

TRxADE HEALTH's stock was trading at $6.20 at the start of the year. Since then, MEDS stock has decreased by 54.9% and is now trading at $2.7962.
View the best growth stocks for 2025 here
.

TRxADE HEALTH, Inc. (NASDAQ:MEDS) released its earnings results on Sunday, October, 24th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by $0.45. The firm earned $2.55 million during the quarter, compared to analyst estimates of $1.94 million. TRxADE HEALTH had a negative net margin of 149.81% and a negative trailing twelve-month return on equity of 196.79%.

TRxADE HEALTH's stock reverse split before market open on Thursday, June 22nd 2023. The 1-15 reverse split was announced on Thursday, June 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of MEDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TRxADE HEALTH investors own include NVIDIA (NVDA), Communications Systems (JCS), Biora Therapeutics (BIOR), Paratek Pharmaceuticals (PRTK), Citius Pharmaceuticals (CTXR), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
10/24/2021
Today
2/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
Wholesale
Current Symbol
NASDAQ:MEDS
Employees
50
Year Founded
N/A

Profitability

Net Income
$-17,840,000.00
Net Margins
-149.81%
Pretax Margin
-250.53%

Debt

Sales & Book Value

Annual Sales
$7.45 million
Book Value
$0.45 per share

Miscellaneous

Free Float
725,000
Market Cap
$4.01 million
Optionable
Not Optionable
Beta
2.32
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:MEDS) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners